 Hoth Therapeutics Inc NASDAQ: HOTH has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces toll-like receptor 2 TLR2 expression, one of the most critical pathways for acne pathophysiology. 